Latanoprostene Bunod (Synonyms: BOL-303259-X, NCX 116, PF-3187207) |
| Catalog No.GC44039 |
El latanoprosteno bunod (LBN), un anÁlogo de la prostaglandina F2a donante de Óxido nÍtrico (NO), es un tratamiento oftÁlmico tÓpico para la reducciÓn de la presiÓn intraocular (PIO) en pacientes con glaucoma de Ángulo abierto o hipertensiÓn ocular (OHT) .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 860005-21-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Latanoproste bunod is a nitric oxide-donating prostaglandin F2α (FP) receptor agonist that is converted to latanoprost (free acid) and nitric oxide (NO) in vivo. It induces cGMP accumulation in PC12 and HEK293 cells (EC50s = 1.6 and 9.2 μM, respectively). Topical administration of latanoprost bunod (0.036% solution) reduces intraocular pressure (IOP) in canine and rabbit models of glaucoma. It also decreases IOP in a cynomolgus monkey model of laser-induced ocular hypertension.
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *